Routes ofadministration Oral Legal status Development terminated PubChem CID 55473 Molar mass 359.47 g/mol | ATC code none CAS Number 76956-02-0 ChemSpider 50093 | |
How to pronounce lavoltidine
Lavoltidine (INN, USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.
References
Lavoltidine Wikipedia(Text) CC BY-SA